Who Is the Winner From The Mylan-Perrigo Merger? Citigroup Says… Teva Pharmaceuticals

In a report published Wednesday, Citigroup analyst Liav Abraham commented on a Mylan NV MYL and Perrigo Company plc PRGO combination, noting that a bid from Teva Pharmaceutical Industries Ltd TEVA is still possible, but challenging. According to Abraham, if Teva is interested in acquiring Mylan, a bid would need to be made in the near-term. A Teva-Mylan combination would generate "material" earnings per share accretion for Teva and would likely be well received by the Street. However, Teva would need to engage in a hostile bid process for the company – made even more complicated by Mylan's recently implemented poison pill. Abraham continued that Teva's strategy of acquiring smaller branded and generic companies will result in a long-term value creation opportunity and provide greater portfolio diversification and a more attractive longer term growth profile. Finally, the analyst suggested that a potential Teva combination with Actavis plc's ACT generics business is preferred over an outright acquisition of Mylan. In fact, the prospect of a potential Mylan sale could entice Actavis to speed up a divestiture of its generics business which isn't considered to be a core strategic asset. Shares of Teva remain Buy rated with an unchanged $70 price target.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsCitigroupLiav AbrahammylanPerrigoSpecialty Pharmaceuticalteva
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!